Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
Authors
Keywords
Wilms tumour, Relapse, High-risk, Trial, Phase I/II, Organoids, SIOP-RTSG, COG, ITCC
Journal
EUROPEAN JOURNAL OF CANCER
Volume 144, Issue -, Pages 113-122
Publisher
Elsevier BV
Online
2020-12-18
DOI
10.1016/j.ejca.2020.11.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study
- (2020) Najat C. Daw et al. JOURNAL OF CLINICAL ONCOLOGY
- An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
- (2020) Camilla Calandrini et al. Nature Communications
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study
- (2019) Amy B. Hont et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation
- (2019) F. Spreafico et al. BONE MARROW TRANSPLANTATION
- Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report
- (2019) David B. Dix et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- Novel therapy for pediatric and adolescent kidney cancer
- (2019) Amy L. Walz et al. CANCER AND METASTASIS REVIEWS
- Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
- (2019) Birgit Geoerger et al. LANCET ONCOLOGY
- Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor
- (2019) Andrew J. Murphy et al. Nature Communications
- A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
- (2018) Paul J. Wood et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I results of a phase I/II study of weekly nab -paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
- (2018) Lucas Moreno et al. EUROPEAN JOURNAL OF CANCER
- A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system
- (2018) Peter E. Manley et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
- (2018) Meredith K. Chuk et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
- (2018) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)
- (2018) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
- (2018) James I. Geller et al. CANCER
- Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?
- (2017) Jesper Brok et al. EUROPEAN JOURNAL OF CANCER
- A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
- (2017) Samantha Gadd et al. NATURE GENETICS
- Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol
- (2017) Marry M. van den Heuvel-Eibrink et al. Nature Reviews Urology
- Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group
- (2017) Janna A. Hol et al. PEDIATRIC BLOOD & CANCER
- Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study
- (2017) Shakeel Modak et al. PEDIATRIC BLOOD & CANCER
- A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)
- (2017) James I. Geller et al. PEDIATRIC BLOOD & CANCER
- Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics
- (2017) Roya Tabatabai et al. Targeted Oncology
- Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
- (2017) Nobuhiro Tsuchiya et al. OncoImmunology
- A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
- (2017) Oren J. Becher et al. PLoS One
- Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
- (2016) Ariadne H.A.G. Ooms et al. CLINICAL CANCER RESEARCH
- Biology and treatment of renal tumours in childhood
- (2016) Jesper Brok et al. EUROPEAN JOURNAL OF CANCER
- Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis
- (2016) Li-Wei Yap et al. Fetal and Pediatric Pathology
- Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study
- (2016) Tasnim Chagtai et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group
- (2016) Eric J. Gratias et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
- (2016) Andrew D.J. Pearson et al. Oncotarget
- Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences
- (2016) Filippo Spreafico et al. Oncotarget
- Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications
- (2016) George D. Cresswell et al. EBioMedicine
- Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors
- (2015) Amy L. Walz et al. CANCER CELL
- Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration
- (2015) Jeffrey S. Dome et al. JOURNAL OF CLINICAL ONCOLOGY
- Stratification of Wilms tumor by genetic and epigenetic analysis
- (2015) Richard H. Scott et al. Oncotarget
- Wilms’ tumor geneWT1promotes homologous recombination-mediated DNA damage repair
- (2014) Yusuke Oji et al. MOLECULAR CARCINOGENESIS
- Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG)
- (2014) A. M. C. Mavinkurve-Groothuis et al. PEDIATRIC BLOOD & CANCER
- TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
- (2014) Mariana Maschietto et al. PLoS One
- Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab
- (2013) Rajkumar Venkatramani et al. PEDIATRIC BLOOD & CANCER
- Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients
- (2012) H. Segers et al. EUROPEAN JOURNAL OF CANCER
- An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour
- (2012) Tam C. Ha et al. EUROPEAN JOURNAL OF CANCER
- Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse
- (2012) Daniela Perotti et al. GENES CHROMOSOMES & CANCER
- Treatment of relapsed Wilms tumors: lessons learned
- (2009) Filippo Spreafico et al. Expert Review of Anticancer Therapy
- Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group
- (2007) Marcio Malogolowkin et al. PEDIATRIC BLOOD & CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now